Clusterin pharmaceuticals and treatment methods using the same
Disclosed are pharmaceutical compositions comprising clusterin and polypeptides substantially the same as clusterin and treatment methods for inflammatory diseases and dry eye disease. The pharmaceutical compositions include an isolated clusterin or an isolated polypeptide substantially the same as clusterin. The clusterin is preferably secreted clusterin. The method of treating dry eye disease includes administering to a patient in need an effective amount of a pharmaceutical composition comprising an isolated clusterin or an isolated polypeptide substantially the same as clusterin. The method of treating a disease state characterized by inflammation includes administering to a patient having the disease state an amount of isolated clusterin or a protein substantially the same as clusterin effective to decrease the activity of a matrix metallproteinase selected from the group consisting of MMP-9, MMP-2 and MMP-7.
1. A method of treating dry eye disease or an ocular surface of an eye at risk for dry eye disease comprising:
topically administering to a patient in need thereof having an eye with an intact ocular surface a pharmaceutical composition comprising an isolated fragment of clusterin, wherein the pharmaceutical composition is administered in an amount sufficient to prevent the intact ocular surface from disruption, and wherein said isolated fragment of clusterin is administered in an amount sufficient to inhibit TNF-alpha induction of MMP-9 and bind and inhibit the activity of MMP-9.
2. The method of claim 1 , wherein the pharmaceutical composition comprises secreted clusterin.
3. The method of claim 1 , wherein the pharmaceutical composition is administered topically as a drop.
4. The method of claim 1 , wherein the pharmaceutical composition further comprises a liquid carrier, and administration is by contacting the pharmaceutical composition to the surface of an eye of the patient.
5. The method of claim 1 , wherein the pharmaceutical composition further comprises a carrier.
6. The method of claim 5 , wherein the pharmaceutical composition is a sterile solution.
7. The method of claim 6 , wherein the pharmaceutical composition is administered topically as a drop.